General MedicationsTOPICALStandard
KLISYRI
TIRBANIBULIN
Standard Dose
1%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview KLISYRI is listed in Drugs@FDA under application 213189 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TIRBANIBULIN Form and strength OINTMENT;TOPICAL - 1% Sponsor ALMIRALL Submission history Latest submission status date: 2024-06-07 00:00:00.
Structured Monograph
Clinical summary
Approval overview KLISYRI is listed in Drugs@FDA under application 213189 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TIRBANIBULIN Form and strength OINTMENT;TOPICAL - 1% Sponsor ALMIRALL Submission history Latest submission status date: 2024-06-07 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.